IL-33 Targeting Shows Promise in Reducing COPD Exacerbations
Recent Phase III trials indicate that inhibiting IL-33 can reduce exacerbations in COPD patients. Tozorakimab, a drug targeting IL-33, is expected to impact the COPD market significantly. Experts highlight IL-33's role in mucus plugs and inflammation, though some aspects of its effects remain unclear, warranting further research.
HCPLive·




